QTTB

Q32 Bio Inc.

Nasdaq · Pharmaceutical Preparations · Inc. DE · CIK 0001661998
$13.11 -6.36% $237.4M
Insider Buying Cluster (2 insiders)High Impact Filing (8/10)3 Institutional Exits
Vol
Market Cap$237.4M
Cap SizeMicro Cap
Analyst ConsensusStrong Buy (82%)
Inst. Holders6 funds
Inst. Value$1.6M
Inst. Activity2 buys / 3 sells
Insider Activity2B / 3S
Insider Net $$19.9M
SEC Reports6
Exchange Nasdaq·Sector Pharmaceutical Preparations·Inc. DE·CIK 0001661998·Prev Close $14.00

Recent Activity

Jun 4, 2026 short_volume
Short Volume: QTTB — 69.8% short (0.5M / 0.7M)
Short: 486,236 | Exempt: 0 | TRF Vol: 696,739 | Short Ratio: 69.8% | Off-exchange volume (dark pool
Jun 2, 2026 SEC
Directors OrbiMed Advisors and Xu Diyong each purchased $10M of QTTB common stock at $8/share on May 28, 2026, for a tot
CLUSTER — Impact 8/10
May 28, 2026 Insider
ORBIMED ADVISORS LLC bought 1,250,000 shares
Director @ $8.00 ($10.0M)
May 28, 2026 Insider
Xu Diyong bought 1,250,000 shares
Director @ $8.00 ($10.0M)
May 5, 2026 SEC
Q32 Bio reported Q1 2026 net loss of $7.6M ($0.54/share), narrower than the $11.0M loss in Q1 2025, driven by lower R&D
8-K — Impact 4/10
Apr 24, 2026 SEC
Q32 Bio Inc. has filed an additional prospectus supplement to raise up to $75 million through its at-the-market (ATM) of
8-K — Impact 6/10
Feb 25, 2026 Insider
Morrison Jodie Pope sold 9,896 shares
CEO @ $4.51 ($44.7K)
Inst.
RENAISSANCE TECHNOLOGIES LLC — DOUBLED
99,600 shares ($330.7K)

Price Targets

$14.25 +8.7% upside Buy
Current $13.11 Low $10.00 Median $13.50 High $20.00 4 analysts
$10.00 $20.00

Analyst Ratings

Strong Buy82% buy · 11 analysts
3Strong Buy
6Buy
2Hold
0Sell
0Strong Sell
Recent Analyst Actions
DateFirmActionRating
May 22, 2026 Mizuho INITIATE Outperform
May 18, 2026 Cantor Fitzgerald INITIATE Overweight
May 5, 2026 HC Wainwright & Co. REITERATE Buy → Buy
Feb 25, 2026 HC Wainwright & Co. INITIATE Buy

Earnings Estimates

PeriodEPS Est.RangeGrowth#
Current Q $-0.56 ▼ -46.8% $-0.66 — $-0.48 28% YoY 5
Next Q $-0.41 ▼ -4.1% $-0.50 — $-0.20 32% YoY 5
Current FY $-1.82 ▲ +13.1% $-2.20 — $-1.24 -175% YoY 5
Next FY $-2.23 ▲ +34.2% $-2.80 — $-1.69 -23% YoY 5

Latest Reports

BULLISH CLUSTER 8/10
Directors OrbiMed Advisors and Xu Diyong each purchased $10M of QTTB common stock at $8/share on May 28, 2026, for a tot
Jun 2, 2026
NEUTRAL 8-K 4/10
Q32 Bio reported Q1 2026 net loss of $7.6M ($0.54/share), narrower than the $11.0M loss in Q1 2025, driven by lower R&D
May 5, 2026

Top Institutional Holders

FundValueMove
VANGUARD GROUP INC$1.1M—
RENAISSANCE TECHNOLOGIES LLC$330.7KDOUBLED
TWO SIGMA INVESTMENTS, LP$155.5KADD
MORGAN STANLEY$18.2KTRIM
FMR LLC$11.2KNEAR_EXIT

Recent Insider Trades

DateInsiderTypeValue
May 28, 2026ORBIMED ADVISORSBUY$10.0M
May 28, 2026Xu DiyongBUY$10.0M
Feb 25, 2026Morrison JodieSELL$44.7K
Feb 25, 2026Violette SheliaSELL$12.7K
Feb 25, 2026Kalowski LeeSELL$18.0K
6 institutional holders with $1.6M total value (477,353 shares) as of 2025-Q4. Top holders: VANGUARD, RENAISSANCE, TWO. Net selling activity: 3 institutions trimmed/exited vs 2 added.

Top Institutional Holders — 2025-Q4

#FundSharesValue% of TrackedLast Move
1VANGUARD GROUP INC321,051$1.1M67.3%—
2RENAISSANCE TECHNOLOGIES LLC99,600$330.7K20.9%DOUBLED +110.6%
3TWO SIGMA INVESTMENTS, LP46,825$155.5K9.8%ADD +48.6%
4MORGAN STANLEY5,478$18.2K1.1%TRIM -51.7%
5FMR LLC3,364$11.2K0.7%NEAR_EXIT -78.8%
6BANK OF AMERICA CORP /DE/1,035$3.4K0.2%TRIM -32.1%

Recent Position Changes

FundActionPrev SharesCurr SharesChange %ValueQuarter
RENAISSANCE TECHNOLOGIES LLCDOUBLED47,30099,600+110.6%$330.7K2025-Q4
TWO SIGMA INVESTMENTS, LPADD31,50646,825+48.6%$155.5K2025-Q4
MORGAN STANLEYTRIM11,3435,478-51.7%$18.2K2025-Q4
FMR LLCNEAR_EXIT15,8673,364-78.8%$11.2K2025-Q4
BANK OF AMERICA CORP /DE/TRIM1,5251,035-32.1%$3.4K2025-Q4
RENAISSANCE TECHNOLOGIES LLCTRIM77,00047,300-38.6%$93.7K2025-Q3
TWO SIGMA INVESTMENTS, LPNEW—31,506—$62.4K2025-Q3
FMR LLCTRIM42,43915,867-62.6%$31.4K2025-Q3
MORGAN STANLEYTRIM18,64811,343-39.2%$22.5K2025-Q3
UBS Group AGTRIM12,5765,246-58.3%$10.4K2025-Q3
BANK OF AMERICA CORP /DE/TRIM2,1981,525-30.6%$3.0K2025-Q3
RENAISSANCE TECHNOLOGIES LLCNEW—77,000—$114.7K2025-Q2
FMR LLCTRIM62,39142,439-32.0%$63.2K2025-Q2
MORGAN STANLEYADD14,65718,648+27.2%$27.8K2025-Q2
UBS Group AGTRIM33,43112,576-62.4%$18.7K2025-Q2
BANK OF AMERICA CORP /DE/TRIM7,2922,198-69.9%$3.3K2025-Q2
WELLS FARGO & COMPANY/MNNEAR_EXIT3,658139-96.2%$207.002025-Q2
CHARLES SCHWAB INVESTMENT MANAGEMENT INCEXIT14,1900-100.0%$0.002025-Q2
FMR LLCADD49,18062,391+26.9%$102.9K2025-Q1
UBS Group AGTRIM47,98233,431-30.3%$55.2K2025-Q1
MORGAN STANLEYNEAR_EXIT72,86214,657-79.9%$24.2K2025-Q1
CITADEL ADVISORS LLCEXIT10,2000-100.0%$0.002025-Q1
TWO SIGMA INVESTMENTS, LPEXIT53,1750-100.0%$0.002025-Q1
MORGAN STANLEYDOUBLED16,51672,862+341.2%$250.6K2024-Q4
UBS Group AGDOUBLED3,64247,982+1217.5%$165.1K2024-Q4
8 unique insiders with 5 transactions. Net insider value: $19.9M ($20.0M bought, $75.4K sold).

Insider Transactions

DateInsiderTitleTypeSharesPriceValue
May 28, 2026ORBIMED ADVISORS LLCDirectorBUY1,250,000$8.00$10.0M
May 28, 2026Xu DiyongDirectorBUY1,250,000$8.00$10.0M
Feb 25, 2026Morrison Jodie PopeCEOSELL9,896$4.51$44.7K
Feb 25, 2026Violette Shelia M.Chief Scientific OfficerSELL2,815$4.51$12.7K
Feb 25, 2026Kalowski LeeCFO and PresidentSELL3,995$4.51$18.0K
Feb 24, 2026Violette Shelia M.Chief Scientific OfficerA37,500$0.00$0.00
Feb 24, 2026Kalowski LeeCFO and PresidentA53,250$0.00$0.00
Feb 24, 2026Morrison Jodie PopeCEOA132,000$0.00$0.00
Jan 15, 2026Lundberg Sven AnteDirectorA20,363$2.75$56.0K
Jan 15, 2026LAPORTE KATHLEENDirectorA23,272$2.75$64.0K
Jan 15, 2026GRAYZEL DAVID S.DirectorA16,363$2.75$45.0K
6 SEC filing reports analyzed. Sentiment: 1 bullish, 3 bearish, 0 mixed, 2 neutral. Avg impact: 5.5/10.
BULLISH CLUSTER 8/10
Directors OrbiMed Advisors and Xu Diyong each purchased $10M of QTTB common stock at $8/share on May
Jun 2, 2026
NEUTRAL 8-K 4/10
Q32 Bio reported Q1 2026 net loss of $7.6M ($0.54/share), narrower than the $11.0M loss in Q1 2025,
May 5, 2026
BEARISH 8-K 6/10
Q32 Bio Inc. has filed an additional prospectus supplement to raise up to $75 million through its at
Apr 24, 2026
BEARISH 424B5 6/10
Q32 Bio Inc. is conducting an at-the-market (ATM) equity offering of up to $75 million in common sto
Apr 24, 2026
BEARISH 424B5 6/10
Q32 Bio Inc. (QTTB) has filed a 424B5 prospectus supplement to register the at-the-market offering o
Mar 27, 2026
NEUTRAL CLUSTER 3/10
Three executive insiders at Q32 Bio Inc. (QTTB) sold shares in a coordinated open-market transaction
Feb 28, 2026
∅

No press releases analyzed yet. Press releases are collected from GlobeNewsWire and analyzed by the LLM pipeline.

Current analyst consensus: Strong Buy (82% buy). Based on 11 analysts: 3 strong buy, 6 buy, 2 hold, 0 sell, 0 strong sell.

Analyst Price Targets

$14.25 mean target +8.7% upside Buy (1.40)
$10.00 Low $20.00 High
MetricValue
Current Price$13.11
Target Low$10.00
Target Mean$14.25
Target Median$13.50
Target High$20.00
# Analysts4
RecommendationBuy (1.40)

Earnings Estimates & Revisions

PeriodEPS AvgEPS LowEPS HighEPS Growth30d Rev.Up/DownRev. AvgRev. GrowthAnalysts
Current Q
2026-06-30
 $-0.56 $-0.66 $-0.48 28.5% -46.8% — $0.0B 0.0% 5
Next Q
2026-09-30
 $-0.41 $-0.50 $-0.20 32.3% -4.1% — $0.0B 0.0% 5
Current FY
2026-12-31
 $-1.82 $-2.20 $-1.24 -175.0% +13.1% 1↑ 0↓ $0.0B -98.1% 5
Next FY
2027-12-31
 $-2.23 $-2.80 $-1.69 -22.8% +34.2% 2↑ 0↓ $0.0B 0.0% 5

Current Quarter EPS Revision History

TimepointEPS EstimateChange
Current$-0.558
7d ago$-0.583+0.025
30d ago$-0.380-0.178
60d ago$-0.380-0.178
90d ago$0.000-0.558
3 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 3 initiations.

Individual Analyst Actions

DateAnalyst FirmActionPrevious RatingNew Rating
May 22, 2026 Mizuho INITIATE — Outperform
May 18, 2026 Cantor Fitzgerald INITIATE — Overweight
May 5, 2026 HC Wainwright & Co. REITERATE Buy Buy
Feb 25, 2026 HC Wainwright & Co. INITIATE — Buy

Monthly Consensus History

PeriodStrong BuyBuyHoldSellStrong SellBuy %Distribution
Jun 1, 20263620082%
May 1, 20263420078%
Apr 1, 20263420078%
Mar 1, 20263420078%
Feb 1, 20263320075%
Jan 1, 20263320075%
Strong BuyBuyHoldSellStrong Sell
∅

No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.

∅

No Reddit sentiment data available yet. Sentiment is analyzed from Reddit investment communities on a rolling basis.

Jun 4, 2026
short_volume
Short Volume: QTTB — 69.8% short (0.5M / 0.7M)
Short: 486,236 | Exempt: 0 | TRF Vol: 696,739 | Short Ratio: 69.8% | Off-exchange volume (dark pool + OTC)
Jun 1, 2026
short_volume
Short Volume: QTTB — 61.0% short (0.3M / 0.5M)
Short: 332,756 | Exempt: 0 | TRF Vol: 545,804 | Short Ratio: 61.0% | Off-exchange volume (dark pool + OTC)
May 29, 2026
short_volume
Short Volume: QTTB — 57.2% short (0.3M / 0.5M)
Short: 308,123 | Exempt: 7,261 | TRF Vol: 538,539 | Short Ratio: 57.2% | Off-exchange volume (dark pool + OTC)
May 7, 2026
earnings_calendar
QTTB Q1 2026 Earnings Scheduled — 2026-05-07
Apr 2, 2026
Clinical Trial
A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA)
Phase Phase 2 — ACTIVE_NOT_RECRUITING
Apr 2, 2026
clinical_trial_readout
T-60d Trial Readout: bempikibart (ADX-914) (Phase 2)
Trial: A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) Sponsor: Q32 Bio Inc. Phase:
Apr 1, 2026
clinical_trial_readout
T-90d Trial Readout: bempikibart (ADX-914) (Phase 2)
Trial: A Phase 2a Proof-of-Concept Trial of Bempikibart (ADX-914) for the Treatment of Severe Alopecia Areata (SIGNAL-AA) Sponsor: Q32 Bio Inc. Phase:
Mar 17, 2026
earnings_calendar
QTTB Q4 2025 Earnings After Market Close — 2026-03-17